All In Biotech

NDA 209089 · Chattem Sanofi

Xyzal Allergy 24hr

Levocetirizine Dihydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: May 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jan 31, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

77

22 Phase 3, 4 recruiting

FAERS reports

9,447

2,266 serious, 287 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 11, 2026.

Uses temporarily relieves these symptoms due to hay fever or other respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 31, 2017 Original approval · Type 8 - Partial Rx to OTC Switch LabelLetterReview
1 products under this application
  • XYZAL ALLERGY 24HR · LEVOCETIRIZINE DIHYDROCHLORIDE 5MG · TABLET, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Levocetirizine Dihydrochloride" as an intervention, any sponsor and status, largest first.

All 77 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,857
  • somnolence1,373
  • fatigue764
  • headache472
  • pruritus425
  • diarrhoea382
  • nausea377
  • dyspnoea376
  • dizziness358
  • insomnia313
  • cough303
  • therapeutic response decreased280

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20055
20065
20073
200815
200925
201018
201178
201261
201326
201433
201554
201685
2017907
20181,509
2019559
2020404
20211,649
2022914
2023837
2024836
2025855
2026569

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 9 on PubMed

Sponsor: Chattem Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.